• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Locust Walk Acquisition Corp.

    8/25/21 4:14:31 PM ET
    $LWAC
    Finance
    Get the next $LWAC alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-39866
    Issuer: Locust Walk Acquisition Corp.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: c/o Ledgewood PC Two Commerce Square
    Suite 3400 2001 Market Street
    Philadelphia PENNSYLVANIA 19103
    Telephone number: 4,156,970,763
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Unit
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2021-08-25 By Tara Petta Director
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LWAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LWAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LWAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Locust Walk Acquisition Corp.

      SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

      9/13/21 6:23:36 AM ET
      $LWAC
      Finance
    • SEC Form SC 13D filed by Locust Walk Acquisition Corp.

      SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

      9/7/21 5:12:00 PM ET
      $LWAC
      Finance
    • SEC Form SC 13D filed by Locust Walk Acquisition Corp.

      SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

      9/3/21 4:00:25 PM ET
      $LWAC
      Finance

    $LWAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Locust Walk Acquisition Corp.'s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies

      SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Locust Walk Acquisition Corp. (NASDAQ:LWAC) ("LWAC" or the "Company"), a special purpose acquisition company, announced today that the Company's stockholders have approved all proposals related to the previously announced business combination (the "Business Combination") with eFFECTOR Therapeutics, Inc. ("eFFECTOR") at a special meeting of stockholders held on August 24, 2021. Approximately 93.2% of the votes cast at the meeting on the Business Combination proposal, representing approximately 71.7% of LWAC's outstanding shares, voted to approve the Business Combination. LWAC stockholders also voted overwhelmingly to approve the other proposals

      8/24/21 4:47:39 PM ET
      $LWAC
      Finance
    • eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer

      SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, announced today the initiation of dosing in the Phase 2a expansion portion of an ongoing Phase 1/2 trial of zotatifin (eFT226) in solid tumors. This followed conclusion of the Phase 1 dose escalation portion of the trial and selection of a recommended Phase 2 dose (RP2D). eFFECTOR expects to initiate multiple indication-specific expansion cohorts in ER+ breast cancer and KRAS-mutant non-small cell lung cancer (NSCLC). Zotatifin will be evaluated both as a single agent and in combination with targ

      8/4/21 8:00:00 AM ET
      $LWAC
      Finance
    • eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

      SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that the first patient has been dosed in a Phase 1b trial evaluating zotatifin (eFT226) as an antiviral agent in an outpatient setting for those with mild to moderate COVID-19 disease. This study is sponsored by a $5.0 million cooperative agreement from the Defense Advanced Research Projects Agency (DARPA) and Defense Health Agency (DHA) and is being conducted in collaboration with the Quantitative Biosciences Institute (QBI) at University of California, San Francisco (UCSF). "Rising case

      7/22/21 8:00:00 AM ET
      $LWAC
      Finance

    $LWAC
    SEC Filings

    See more

    $LWAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form S-1/A filed by Locust Walk Acquisition Corp.

      S-1/A - LightWave Acquisition Corp. (0002061379) (Filer)

      6/9/25 8:37:32 AM ET
      $LWAC
      Finance
    • SEC Form EFFECT filed by Locust Walk Acquisition Corp.

      EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)

      10/6/21 12:15:17 AM ET
      $LWAC
      Finance
    • SEC Form 424B3 filed by Locust Walk Acquisition Corp.

      424B3 - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)

      10/5/21 4:24:26 PM ET
      $LWAC
      Finance
    • SEC Form 4 filed by Ehrlich Christopher B

      4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)

      10/8/21 5:22:23 PM ET
      $LWAC
      Finance
    • SEC Form 4 filed by Bhatt Elizabeth

      4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)

      10/8/21 5:20:18 PM ET
      $LWAC
      Finance
    • SEC Form 4 filed by Smither John W

      4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)

      10/8/21 5:18:52 PM ET
      $LWAC
      Finance